+86-571-8627 3270
INNER MONGANIA YUANHONG FINE CHEMICAL CO.,LTD
10 YRS
Inner Mongolia, China
CNY 188 Million
199800 m²
100-500 people
Main Products: 3-Amino-3-Azabicyclo[3.3.0]Octane Hydrochloride / 2-Anilino-6-Dibutylamino-3-Methylfluoran / 3-Hydroxy-2-(1,3-Indandione-2-Yl)Quinoline / 2-Amino-3-Methylphenol / 2,2'-Dinitrodibenzyl / 2,4,5-Trifluoro-3-Methoxybenzoyl Chloride / 9,10-Difluoro-2,3-Dihydro-3-Methyl-7-Oxo-7H-Pyrido[1,2,3-De]-1,4-Benzoxazine-6-Carboxylic Acid / (S)-Ethyl 9,10-Difluoro-3-Methyl-7-Oxo-3,7-Dihydro-2H-[1,4]Oxazino[2,3,4-Ij]Quinoline-6-Carboxylate
Inner Mongolia, China
ABOUT US
Inner Mongolia Yuanhong Fine Chemical Co., Ltd., established on September 4, 2014 with a registered capital of 188 million yuan, is the first pharmaceutical API and pharmaceutical intermediate production and R & D enterprise settled in Wuda Industrial Park, Wuhai economic development zone. The company has enterprise management department, administrative personnel department, finance department, production equipment department, engineering project department, quality technology department, quality inspection department, safety supervision department, environmental protection department, procurement department, sales department and other functional departments and production units. Adhering to the development concept of "science and technology leads the future and innovation drives development", our company has built a R &D center covering an area of 4500 square meters. The laboratory of the R &D center is equipped with gas-liquid chromatograph, infrared spectrometer and other advanced detection and R &D equipment at home and abroad. In cooperation with scientific research institutes such as Zhejiang University, Lanzhou University and Xiamen University, it has successively developed a series of products such as oxyfluorocarboxylic acid, levofloxacin, levofloxacin, gatifloxacin and cefixime side chain active ester, It has a number of patented technologies with independent intellectual property rights. In December 2016, it was approved as "autonomous region level enterprise R &D center". In 2016, the company's R & D of ofloxacin intermediates was listed as a strategic emerging industry project in Inner Mongolia Autonomous Region, filling the industrial gap in the autonomous region. In 2018, our company was recognized as a "high-tech enterprise at the level of autonomous region", and the "high-tech enterprise certificate" was issued in October of the same year.
Basic Information
Tax ID
91150304MA0MWL6Y5B
Country/Region
Inner Mongolia, China
Year Established
2014
Registered Capital
CNY 188 Million
Business Type
CRO
Total Employees
100-500 people
Quality Management Certificate
-
Total Annual Revenue
CNY 1000 Million
Enterprise Ownership
Private Owned
Is This Your Own Factory
Yes
Summary Up
Pharmaceutical raw materials and pharmaceutical intermediates manufacturing and R & D Enterprises
PLANT LOCATION
COMPANY ALBUM
厂房大门
办公区域
公司活动
公司活动
公司活动
其他图片
CERTIFICATES
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >